Clinicopathologic Features of Operated Gastrointestinal Stromal Tumors
Aysegul Ilhan1, Emrah Eraslan1, Nazan Demir2, Ferit Aslan3, Fatih Yildiz11Department of Medical Oncology, University of Health Sciences Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara,Turkey, 2Department of Medical Oncology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey, 3Division of Medical Oncology, Yuksek Ihtisas University, Medical Park Hospital , Ankara,Turkey
Objectives: We aimed to evaluate the clinicopathological features and clinical outcomes of patients with resected Gastrointestinal stromal tumors (GISTs). Methods: This study was a retrospective, multicenter cohort study. Patients diagnosed with a GIST, 18 years of age and older, operated on R0, between January 2005 and May 2020 were included in the study. Patient with metastatic disease at diagnosis were excluded. Results: Of 104 patients, the median age was 61 years (35-87) and 58.7% (n=61) were male. The most common location was stomach (n: 52.5%). According to The Modified-National Institutes of Health (M-NIH) classifications, 52 (50%) patients were in the high-risk group. The median relapse-free survival (RFS) was 62.1 (95% CI; 52.7-71.5) months. Increased aged at diagnosis (HR=0.952, 95% CI 0.910-0.995, p=0.030), Ki-67<10% (HR=5.007, 95% CI 1.503-16.680, p=0.009), low risk M-NIH category (HR=21,083, 95% CI 2.119-209.769, p=0.009), two-year adjuvant imatinib (HR= 0.255, 95% CI 0.070-0.920, p=0.037) or three-year treatment (HR=0.191 95% CI 0.040-0.919, p=0.039) were independent factors for RFS. Conclusion: High ki-67 index and high M-NIH score are factors that have a negative effect on relapse. Keeping the adjuvant treatment period longer than one year and advanced age have a positive effect on recurrence. Keywords: gastrointestinal stromal tumors , adjuvant imatinib treatment , relapse-free survival
Cite This Article
Ilhan A, Eraslan E, Demir N, Aslan F, Yildiz F. Clinicopathologic Features of Operated Gastrointestinal Stromal Tumors. EJMI. 2022; 6(2): 210-216
Corresponding Author: Aysegul Ilhan